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The parasitic worm-derived 
immunomodulator, ES-62 and its 
drug-like small molecule analogues 
exhibit therapeutic potential in a 
model of chronic asthma
J. C. Coltherd1,*, D. T. Rodgers1,*, R. E. Lawrie1, L. Al-Riyami2, C. J. Suckling3, W. Harnett2 & 
M. M. Harnett1
Chronic asthma is associated with persistent lung inflammation and long-term remodelling of the 
airways that have proved refractory to conventional treatments such as steroids, despite their efficacy 
in controlling acute airway contraction and bronchial inflammation. As its recent dramatic increase 
in industrialised countries has not been mirrored in developing regions, it has been suggested that 
helminth infection may protect humans against developing asthma. Consistent with this, ES-62, an 
immunomodulator secreted by the parasitic worm Acanthocheilonema viteae, can prevent pathology 
associated with chronic asthma (cellular infiltration of the lungs, particularly neutrophils and mast cells, 
mucus hyper-production and airway thickening) in an experimental mouse model. Importantly, ES-62 
can act even after airway remodelling has been established, arresting pathogenesis and ameliorating 
the inflammatory flares resulting from repeated exposure to allergen that are a debilitating feature of 
severe chronic asthma. Moreover, two chemical analogues of ES-62, 11a and 12b mimic its therapeutic 
actions in restoring levels of regulatory B cells and suppressing neutrophil and mast cell responses. 
These studies therefore provide a platform for developing ES-62-based drugs, with compounds 11a 
and 12b representing the first step in the development of a novel class of drugs to combat the hitherto 
intractable disorder of chronic asthma.
Asthma, a chronic ailment of the lungs associated with airway inflammation and exaggerated responses to infec-
tions, allergens and irritants, has increased dramatically in many developed countries, with prevalence highest 
in children1. However, such an increase has not been mirrored in rural areas of the Third World where parasitic 
helminths (worms) are highly abundant (see2) and this has led to the suggestion that such pathogens may protect 
humans from developing asthma. Although the situation is not clear-cut, being influenced by factors such as the 
species of helminth under study (reviewed by3,4), there is certainly sufficient supportive evidence, reinforced by 
the increasing body of data revealing that parasitic worms, or their secreted immunomodulatory products, can 
prevent the development of allergic inflammation in the lungs in mouse models (reviewed in3,4). In turn, this 
has generated interest in clinical trials of ‘worm therapy’ in allergy and asthma4 as well as in the exploitation of 
worm-derived immunomodulators to develop novel drugs for such diseases5.
Amongst the best-characterized secreted products with anti-allergy properties is ES-62, a phosphorylcho-
line (PC)-containing glycoprotein derived from the filarial nematode Acanthocheilonema viteae5. ES-62 directly 
blocks mast cell activation, thereby preventing inflammatory mediator release, both in vitro and also in vivo 
in the ovalbumin (OVA)-induced airway hyper-reactivity (OAH) BALB/c mouse model of acute asthma6,7. In 
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addition, in this OAH model, ES-62 protects against cellular infiltration (eosinophils and neutrophils) and con-
sequent inflammation-induced pathology in the lungs via blockage of Th17 responses and reversal of Th2 cell 
polarization. The mechanisms involved are not yet fully delineated but induction of IFNγ +Tbet+CD8+ T cells 
appears to play a key role and indeed, ES-62’s protective actions are blocked by administration of neutralising 
anti-IFNγ antibodies suggesting that the parasite product acts to homeostatically reset the Th cell balance in this 
acute airway inflammation model6,8. To date however, despite the wealth of evidence supporting the protective 
effects of helminth infection and worm-derived immunomodulatory products in mouse models of acute airway 
inflammation, clinical trials of “worm therapy” in asthma, albeit inducing some (non-significant) improvement 
in airway responsiveness9, have proved disappointing4. Such lack of improvement in asthma control might per-
haps suggest a failure of the gastrointestinal worms tested to date to arrest or reverse pathology associated with 
chronic asthma such as the airway remodelling10,11 that has also proved refractory to conventional treatments 
despite their efficacy in controlling acute airway contraction and bronchial inflammation. Of interest given the 
effects of ES-62 on mast cells, there is increasing evidence that inflammatory responses triggered by the infiltra-
tion of airway smooth muscle bundles by mast cells may play a major role in airway remodelling: the resulting 
production of growth factors, chemokines, contractile mediators and matrix metalloproteinases are responsible 
for the eosinophil and neutrophil influx, increased mucus secretion and phenotype of extracellular matrix dep-
osition that collectively contribute to the augmented airway inflammation and remodelling observed in chronic 
asthma10,11. Mast cells have also been reported to promote many of the parameters (cellular infiltration of the 
lungs and enhanced inflammation and airway hyper-responsiveness, goblet cell hyperplasia as well as increased 
expression of mucins 5AC and 5B and collagen deposition) associated with chronic asthma in humans12. We have 
therefore now investigated the therapeutic potential of ES-62 in a C57BL/6 mouse model in which mast cells 
promote chronic OVA-induced airway hypersensitivity and airway remodelling12.
Materials and Methods
Chronic asthma model. Female C57BL/6J mice (6-8 weeks old) were purchased from Harlan Olac (Bicester, 
UK) and group-housed at the University of Glasgow. Water and normal mouse chow were provided ad libitum 
and mice were monitored daily. All procedures were conducted in accordance with Home Office, UK animal 
guidelines and with the approval of the Ethical Committees of the Universities of Glasgow and Strathclyde (PPL 
60/3580; PPL 60/3791; PPL 60/4300; PIL 60/10892; PIL 60/12183 and PIL60/12950). Purified, endotoxin-free 
ES-62 from the rodent filarial nematode A. viteae and its small molecule analogues (SMAs) 11a and 12b were 
prepared as described previously8,13,14. The OVA-induced model of chronic asthma was performed as previously 
described12. Briefly, female C57BL/6J mice were sensitised to OVA by intraperitoneal injection of OVA (50 μ g in 
PBS) at days 0, 3 and 6. These mice were challenged with weekly intranasal instillations of OVA (20 μ g in PBS) 
and, where indicated, subcutaneous injections of ES-62 in PBS (2 μ g in 100 μ l), SMA 11a or 12b in PBS (1 μ g in 
100 μ l) or PBS alone at the relevant time point(s) starting from day 11 up to day 67. Unless otherwise indicated, 
mice were sacrificed at day 69 and serum, lungs, draining lymph nodes (DLN) and spleens were harvested, and 
bronchoalveolar lavage fluid (BALF) collected by cannulation of the trachea and flushing with PBS. Following 
fixation (10% (w/v) paraformaldehyde) and snap freezing in OCT, lung sections (7 μ m) were scored blindly6 
for disease parameters (cellular infiltration, airway thickening, mucus production and collagen deposition) on 
a 0–4 point scale, where 0 = normal, 1 = mild, 2 = moderate, 3 = substantial and 4 = severe, following staining 
with haematoxylin and eosin (H&E), Periodic Acid-Schiff (PAS), Gomori’s Trichrome or Toluidine Blue. Airway 
thickening was scored from all immunohistochemical staining of sections, cellular infiltration was scored from 
H&E and Gomori’s Trichrome sections, collagen deposition was scored from Gomori’s Trichrome sections and 
mucus production was scored from PAS sections6,8,14. The number of degranulating/degranulated and intact mast 
cells were calculated from Toluidine Blue sections. As multiple fields/section were scored, the mean value for each 
mouse was plotted and analysed. When a condition was only quantified from one staining method, between 3 
and 15 fields per section were scored per mouse per time point. The phenotype and number of cells present in the 
BALF were determined by light microscopy6,8,14.
Cytokine and antibody analysis. The levels of cytokines and other molecules in the BALF were measured 
by ELISA: IL-4, IL-13, MCP-1, IL-17A, IL-17F and IL-25 (eBioscience) and IL-22, eotaxin 1, eotaxin 2 and perios-
tin (R&D systems) analysis was performed in accordance with manufacturers’ protocols. OVA-specific antibody 
levels in titrated serum were similarly measured by a sandwich assay, using OVA (plates coated at 20 μ g/ml in 
PBS) and biotin-conjugated-anti-mouse IgG1, IgG2a or IgE (all from BD) antibodies, streptavidin (sv)-HRP and 
TMB substrate6,8.
Flow cytometry. Flow cytometric analysis of B cell populations was performed using our previously 
described gating strategies8,15–17. Following red cell lysis, cells were counted and stained with a cocktail of antibod-
ies for the detection of the indicated populations using anti-CD19-AF700, anti-CD23-PE/Cy7, anti-CD21-E450, 
anti-CD43-PE/Cy7, anti-GL7-FITC, anti-CD138-PE, anti-B220-E450, anti-B220-APC, anti-IL-10-APC, 
anti-CD3-FITC, anti-CD4-PerCP and anti-CD8-PE/Cy7 antibodies from eBioscience and Biolegend. Plasma 
cells were phenotyped as (Dump (CD3, CD4, CD8, CD11b, GR1 & CD11c)− CD138+CD19−B220−) with the 
Dump+ markers identified using biotinylated antibodies and svPE. Alternatively, splenocytes were stimulated 
with 50 ng/ml PMA (Sigma-Aldrich, UK) plus 500 ng/ml ionomycin (Sigma-Aldrich, UK) and 10 μ g/ml LPS (E. 
coli O111:B4, Sigma-Aldrich, UK) for 1 h before addition of 10 μ g/ml Brefeldin A (Sigma-Aldrich, UK) and cells 
were then incubated for a further 5 h at 37 °C with 5% CO2. Cells were fixed and washed several times in perme-
abilization buffer before anti-IL-10 was added in permeabilization buffer and incubated at 4 °C for 30 minutes. 
Cells were then washed three times with permeabilization buffer and finally with FACs staining buffer before data 
were acquired using a BD LSR II flow cytometer and analysis undertaken by FlowJo software (TreeStar).
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Immunofluorescence analysis. Lung expression of MyD88 and Collagen VI was visualised by staining 
tissue sections (7 μ m) with a polyclonal anti-human/mouse MyD88 antibody (eBioscience; 1:500 dilution) and 
FITC-labelled anti-rabbit IgG secondary antibody (1:200 dilution) or a rabbit polyclonal anti-Collagen VI anti-
body (1:200 dilution), biotinylated anti-rabbit IgG antibody (1:200 dilution) and streptavidin-AF647 (1:200 dilu-
tion), with DAPI (diluted to 1:10000 in PBS) used as a counterstain. Images were obtained using an LSM 510 
META confocal laser coupled to an Axiovert 200 microscope (Zeiss) and analysed by Zeiss LSM Image Browser 
software.
qRT-PCR analysis. Total RNA was extracted using an RNeasy plus kit (Qiagen) and ≤ 1 μ g of RNA was used 
to synthesize cDNA (Applied Biosystems). TaqMan® RT-PCR was performed using the relevant TaqMan® Gene 
Expression Assays from Applied Biosystems; periostin (Mm00450111_m1), muc5ac (Mm01276718_m1), muc5b 
(Mm00466391_m1), tlr4 (Mm00445273_m1) and myd88 (Mm00440338_m1). Polymerase chain reactions were 
performed in triplicate in a StepOne sequence detector (Applied Biosystems). Data analysis was performed 
using the Applied Biosystems sequence detection software and the reference reporter, mouse glyceraldehyde 
3-phosphate dehydrogenase (GAPDH; Mm99999915_g1), was used as an endogenous control.
Statistical analysis. Statistical analysis was by one-way or two-way ANOVA (parametric data) or 
Kruskal-Wallis (non-parametric) with Bonferroni/Dunn’s post-tests or by t-test/Mann-Whitney analysis as 
appropriate using GraphPad Prism software. Treatments were considered significant when *p < 0.05.
Results
Characterisation of lung pathology in the (non-adjuvant) OVA C57BL/6 mouse model of chronic 
asthma. The aim of the study was to establish whether ES-62 could prevent and/or arrest features of lung 
pathology associated with chronic asthma that have proved refractory to current treatments. Thus, the kinetics 
of development of associated histopathological parameters including cellular infiltration, and more specifically 
the presence of intact and degranulated mast cells, mucus production, collagen deposition and airway wall thick-
ening were monitored to establish the onset of the airway remodelling characteristic of chronic asthma (Fig. 1a). 
Typically, cellular infiltration of the lungs, which is associated with both acute and chronic phases of asthma, 
was found to be elevated by d24, and to further significantly increase throughout the time course (Fig. 1b), 
whilst features more restricted to chronic asthma, such as airway thickening, could only be detected at later time 
points (d40), peaking around d55 (Fig. 1c). Mast cells could be detected throughout the time course: following a 
decrease in the levels of degranulated mast cells towards the end of the acute phase (d24), and perhaps consistent 
with their proposed role in airway remodelling, there appeared to be a late peak in their levels between d48-62 
(Fig. 1d). Perhaps surprisingly, there was no significant increase in total collagen deposition detected (Fig. 1e), 
but this might simply reflect masking of significant changes in types such as collagen VI which have been associ-
ated with airway remodelling in chronic asthma18. However, reflecting induction of a chronic asthma phenotype, 
mucus production was found to progressively increase with time and OVA challenge (Fig. 1f).
Supporting the histopathology data, analysis of the bronchoalveolar lavage fluid (BALF) revealed that elevated 
levels of eosinophils and neutrophils could be detected by d24, peaking about d30 although there was a secondary 
peak around d55 coinciding with the period of airway remodelling (Fig. 1g). Preceding the primary recruitment 
of eosinophils and neutrophils19, there were early slight (reflecting the lack of Alum adjuvant) elevations in the 
levels of IL-4, IL-13 (IL-13 day 5, p < 0.05; Fig. 2a) and IL-17F (day 10, p < 0.05; Fig. 2b): MCP-1 production was 
substantially increased within days (day 10, p < 0.05), but this was generally maintained throughout (Fig. 2c). By 
contrast, the kinetics of eotaxin-1 and eotaxin-2 (Fig. 2c) and periostin (Fig. 2d) were more consistent with the 
late phase recruitment of these cell types (Fig. 1g) as well as the recently proposed role of periostin in promoting 
airway remodelling20. Levels of lymphocytes were only slightly elevated after d40 (p < 0.001; Fig. 1g), and this was 
perhaps reflected in the generally low levels and slow kinetics of detection of IL-17E (IL-25) and IL-22 expression 
in the BALF (Fig. 2b). During this period plasma cells (PC; peak d48) were also detected in the BALF (Fig. 2e) 
perhaps reflecting the proposed pathogenic role of IgE in asthma. Consistent with this, OVA-specific IgE could 
be detected in the BALF from d24 (Fig. 2e) and there was also a late serum peak observed (d49-69; Fig. 2f) typ-
ical of chronic asthma21. By contrast, OVA specific IgG1, but not IgG2a, was detectable by d17 with the strongly 
elevated levels observed between d33-69 potentially acting to perpetuate Th2-like inflammation22, although this 
pathogenic role for IgG in the form of immune complexes remains controversial in human asthma22. Analysis of 
the splenic B cell population dynamics underlying these responses revealed a primary plasma cell (PC) response 
during the sensitization period associated with a corresponding drop in GC cells (Fig. 2g). The PC pattern was 
repeated, initiating around d18 and d48, the former corresponding with the elevations in BALF IgE and serum 
IgG1 whilst the latter is likely associated with the late serum peaks in IgG1, IgG2a and IgE (Fig. 2f). Reflecting 
these effector B cell dynamics, IL-10+ B (Breg) and Tr1 cell populations were found to expand during the onset of 
pathology, presumably acting to counter-regulate the developing inflammatory response, before fading away from 
d24 during the established disease phase (Fig. 2h).
ES-62 prevents development of features of airway remodelling associated with chronic 
asthma. Treatment of mice with ES-62 (ES1; weekly from d11; Fig. 3a) significantly reduced the cellular 
infiltration of the lungs (Fig. 3b,f), hyperproduction of mucus (Fig. 3c,g), mast cell infiltration (Fig. 3d) collagen, 
particularly Collagen VI deposition (Fig. 3e,h) and airway thickening (Fig. 3b,i) associated with chronic challenge 
with OVA (Fig. 1). These protective actions of ES-62 appeared unlikely to reflect generalized, sustained immuno-
suppression as when the parasite product was only administered weekly from d11-d32 (ES2), all protective effects 
were lost by d69 (Fig. 3f–i), indicating a reversible mechanism of action.
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Figure 1. Lung pathology in the C57BL/6 mouse model of chronic asthma. (a) Representative images of 
H&E staining of airway thickness and cellular infiltration, PAS staining of goblet cells and mucus production, 
Gomori’s Trichome staining showing collagen deposition and Toluidine Blue staining of mast cells. Scale bars of 
images are 200 μ m (x10 magnification). Scoring of airway disease parameters from immunohistochemical  
tissue sections (b–f) showing the means ± SEM of the mean values of individual mice where n = 5 mice  
culled for each time point and where *p < 0.05, **p < 0.01 and ***p < 0.001 relative to the score on day 0.  
(b) cellular infiltration; (c) airway thickening; (d) intact/degranulated mast cells; (e) collagen deposition; 
(f) mucus production. (g) Mean counts ± SEM of total BALF cells and eosinophils, neutrophils and 
lymphocytes in BALF where n = 5–13 individual mice culled at each time point. Total and Differential 
(eosinophils, neutrophils and lymphocytes) counts are scaled on the left and right hand y-axes, respectively.
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Figure 2. Inflammatory parameters of the C57BL/6 mouse model of chronic asthma. (a) IL-4 and IL-13 
in the BALF are presented as mean ± SEM values of the mean levels with respect to individual mice (n = 5) 
at each time point; (b) IL-17E (IL-25; n = 5), IL-17F (n = 5) and IL-22 (n = 3) in the BALF are presented as 
mean ± SEM values of the mean levels in the indicated numbers of individual mice at each time point;  
(c) MCP-1 (n = 5), exotaxin-1 (n = 5–8) and eotaxin-2 (n = 5–8) in the BALF are presented as mean ± SEM 
values of the mean levels in the indicated numbers of individual mice at each time point; (d) Periostin in the 
BALF is presented as mean ± SEM values of the mean levels in individual mice (n = 3–5) at each time point; 
(e) OVA-specific IgE in the BALF is presented as mean ± SEM values of the mean OD450 values for individual 
mice (n = 3–4) at each time point whilst the levels of plasma cells (PC) in pooled samples at each time point 
are presented as the % of live BALF cells; (f) OVA-specific IgE, IgG1 and IgG2a levels in serum are presented as 
mean ± SEM values of the mean OD450 values for individual mice (n = 5) at each time point; levels of splenic 
germinal centre (GC) B cells and PC (g) and IL-10+ Breg and Tr1 cells (h) presented as mean % ± SEM values of 
individual mice (n = 5) at each time point.
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The protective effects of ES-62 were further corroborated by the reduced levels of cells, specifically, neutro-
phils found in the BALF (Fig. 4a) and which, consistent with their expression of CCR323, were associated with 
reductions of the CCR3 ligand, eotaxin-2 (CCL24; Fig. 4b) to levels not significantly different to those found in 
PBS-treated mice. Exposure to ES-62 did not suppress either BALF or serum levels of IgE (results not shown) 
and whilst it reduced serum IgG1 levels (at a 1/200 dilution; Fig. 4c) it did not modulate IgG2a levels (results not 
shown). In addition, exposure to ES-62 resulted in downregulation of expression of periostin and the mucins, 
Muc5AC and Muc5B in lung tissue (Fig. 4d): consistent with previously published studies showing bacterial 
and environmental-mediated upregulation of Muc5AC and Muc5B by respiratory epithelial cells to be TLR/
MyD88-dependent24,25, we also found exposure to ES-62 acted to downregulate expression of TLR4 (Fig. 4e) and 
Figure 3. ES-62 prevents and arrests development of pathology associated with chronic asthma. (a) Time-
course protocols of administration of ES-62 in the OVA-induced C57BL/6 mouse model of chronic asthma. 
(b) Representative images of H&E staining of lung sections at various time points during OVA-induced airway 
pathology and the effect of administering ES-62 weekly either from day 11 (ES1) or day 46 (ES3). Representative 
images of PAS (c) or Toluidine blue (d) staining of day 69 lung sections following OVA-induced airway 
pathology and the effects of ES1 and ES3 treatment. “PBS” represents mice that have been treated with PBS 
rather than OVA. (e) Immunofluorescence analysis of collagen VI (pink) and nuclear (DAPI; blue) staining in 
day 69 lung sections from the PBS-, OVA- or ES1 groups. Scoring of the effect of ES-62 treatment on airway 
disease parameters from immunohistochemical tissue sections (f–i) showing the mean values of the indicated 
numbers of individual mice at day 69 where *p < 0.05, **p < 0.01 and ***p < 0.001 relative to the OVA score.
www.nature.com/scientificreports/
7Scientific RepoRts | 6:19224 | DOI: 10.1038/srep19224
MyD88 in the lung (Fig. 4e,f), both of which have been shown to promote development of airway inflammation 
in response to inhaled antigen26,27 and are elevated in the OVA-, relative to PBS-treated mice.
ES-62 can arrest established airway remodelling in chronic asthma. In addition to determining 
whether ES-62 could prevent development of features (airway remodelling and neutrophil infiltration) associated 
with chronic severe asthma, we investigated whether treatment with ES-62 could arrest or even reverse develop-
ment of established airway remodelling since this phenomenon is refractory to current therapeutic regimes. As 
the onset of the key parameters associated with this are well established by d46 (Figs 1 and 3), we determined 
Figure 4. ES-62 protects against inflammation in the chronic asthma model. (a) Total and differential 
neutrophil cell counts in the BALF of the indicated number of individual mice from the PBS-, OVA- and ES1-
groups at day 69, where *p < 0.05 relative to the OVA group. (b) Mean values of eotaxin2 in the BALF of the 
indicated number of individual mice from the PBS-, OVA- and ES1-groups at day 69, demonstrating that the 
mean ± SEM levels in the OVA, but not ES1, group are significantly (*p < 0.05) different to those in PBS-treated 
mice. (c) ES-62 reduces the levels of OVA-specific IgG1 in serum where *p < 0.05 for the mean ± SEM of mean 
values of the indicated number of ES1 versus OVA mice. (d) qRT-PCR analysis of mRNA levels of periostin, 
muc5ac and muc5b where data are presented as the mean of mean 2−ΔΔCt values for individual mice and where 
***p < 0.001 for ES1 versus OVA groups of mice. (e) qRT-PCR analysis of mRNA levels of tlr4 and myd88  
where data are presented as the means ± SEM of mean 2−ΔΔCt values for 3 individual mice in each group.  
(f) Immunofluorescence analysis of MyD88 (green) and nuclear (DAPI; blue) staining in day 69 lung sections 
from the PBS-, OVA- ES1- and ES4 groups.
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whether weekly treatments with ES-62 from this point onwards (ES3; Fig. 3a) prevented further subsequent 
development of lung pathology. This revealed that such therapeutic treatment arrested the further development of 
cellular infiltration (Fig. 3b,f), mucus hyperproduction (Fig. 3c,g), collagen deposition (Fig. 3h) and airway thick-
ening (Fig. 3i) and indeed, appeared to reverse some of the histopathology evident at the start of the treatment 
(Fig. 3b): although scoring of the sections did not show a significant reduction in airway thickening in relation 
to the OVA group, some degree of improvement was evident as these ES3 scores were not significantly different 
from those resulting from the “prophylactic” ES1 treatment (Fig. 3i). Collectively, these data suggest that therapies 
based on ES-62 may be able to protect against future deterioration of lung function or even reverse an established 
chronic asthma lung phenotype somewhat.
ES-62 ameliorates allergen-induced neutrophil exacerbations in chronic asthma. Inflammatory 
flares consequent to repeated exposure to allergen are a debilitating feature of severe chronic asthma. Thus, to 
investigate whether in addition to arresting airway remodelling ES-62 can act therapeutically to ameliorate such 
exacerbations, we tested the effects of administering it immediately prior to the final challenge with OVA (ES4; 
Fig. 3a). This revealed that whilst, as expected, this treatment had no substantial immediate effect on mucus pro-
duction or airway thickening (Fig. 5a), it reduced cellular infiltration (mean score ± SEM: PBS, 2.618 ± 0.2; ES-62, 
1.995 ± 0.19: p ≤ 0.05). Reflecting this, although the total cellularity of the BALF in the ES4 group was not signif-
icantly different from that of the OVA control mice (Fig. 5b) there was a significant decrease in the levels of neu-
trophils (Fig. 5c), but not macrophages, lymphocytes or eosinophils (results not shown), recruited. However, this 
inhibitory effect on neutrophil infiltration was not associated with significant suppression of the levels of the Th2 
(IL-4 and IL-13)- or Th17 (IL-17A, -E, F or IL-22)-associated cytokines, chemokines (eotaxin-1, -2 or MCP-1) or 
the inflammatory mediator, periostin (results not shown) implicated in the recruitment of pro-inflammatory cells 
to the airways during asthma pathogenesis. Rather, this ES-62-mediated amelioration of OVA-induced neutro-
philic exacerbation was accompanied by a downregulation in MyD88 expression in the lung (Fig. 4f) and restora-
tion of the putative regulatory IL-10-producing splenic B cell population (Bregs) back towards the levels observed 
in naive mice (Fig. 5d). By contrast, this ES-62 treatment had no effect on the levels of splenic CD19−IL-10+ 
lymphocytes (surrogate for regulatory T cells, particularly Tr1 cells; Fig. 5e), a finding perhaps consistent with 
Figure 5. ES-62 ameliorates OVA-induced inflammatory exacerbations. (a) Representative images of 
H&E and PAS staining of day 69 lung sections from OVA- and ES4 groups of mice. Total (b) and differential 
neutrophil (c) cell counts in the BALF of individual mice in the indicated treatment groups where in (b), the 
mean ± SEM value of the OVA, but not the ES4, group is significantly (*p < 0.05) different to that of the PBS 
mice whilst in (c), the levels of neutrophils in the ES4 group are significantly reduced (**p < 0.01) relative to 
those found in OVA mice. The levels of splenic IL-10+ Breg (d) and CD19−IL-10+ lymphocytes (e) presented 
as the % live cells in individual mice (n = 5) and where for the mean ± SEM values, **p < 0.01 and ***p < 0.001 
relative to that of the OVA group. In (f), the levels of MZ (CD21+CD23±) and MZP (CD21+CD23+)-like Bregs 
are presented as the % of IL-10+ B cells in the spleen of the indicated number of individual mice and where for 
the mean ± SEM values, *p < 0.05 relative to that of the OVA group. (g) Levels of splenic MZ Bregs presented as 
mean % ± SEM values of individual mice (n = 5) at each time point. Levels of MZ-like B cells in pooled samples 
from each group at the indicated time points (from d24) are presented as the % of live BALF cells.
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the ES-62-mediated restoration of CD19+IL-10+ levels reflecting an increase in the MZ (CD21+CD23±), but not 
MZP (CD21+CD23+), -like Bregs (Fig. 5f) that have been reported to be involved in the IL-10-, but not regulatory 
T cell-dependent protection afforded in models of acute OVA-induced AHR following infection with the parasitic 
trematode worm, Schistosoma mansoni28. ES-62 had no effect on any of the other proposed phenotypes of Breg 
(Follicular, B1, B10 and plasmablast) analysed (results not shown).
These data therefore suggested that ES-62 might act to reset the homeostatic balance of effector: regulatory 
B cells that normally acts to resolve aberrant airway inflammation. Consistent with this, determination of the 
levels of MZ-like Bregs in the spleen (Fig. 5g), showed that in contrast to the total levels of Bregs (Fig. 2h), which 
progressively rise during the initiation phase of disease (peaking at d25) presumably as a homeostatic response 
to increasing inflammation, MZ-like Bregs decrease during this period (trough at d17), displaying an essentially 
inverse pattern to that of GC B cells (Fig. 2g). Likewise, their sustained reduction from d40-onwards precedes the 
late rise in splenic GC B cells and plasma cells observed at d62 in the spleen. Moreover, analysis of BALF levels 
of MZ-like B cells (as a phenotypic surrogate of MZ-like Bregs in the airways) from d24 showed their profile to 
generally shadow that of MZ Bregs in the spleen (Fig. 5g): collectively, these data perhaps suggest a particular 
correlation between decreases in MZ Bregs and airway inflammation that ES-62 targets to prevent development 
of pathology associated with chronic asthma.
We next investigated whether the protection afforded by the prophylactic ES1 and therapeutic ES3 (post-onset 
of lung pathology associated with chronic asthma) interventions also reflected resetting of IL-10+Bregs lev-
els: analysis at d69 cull suggested that prophylactic treatment with ES-62 (ES1) did not modulate the levels of 
either MZ- or MZP-like Bregs (Fig. 6a) and indeed, if anything each of the ES1 and ES3, but not the ES2, treat-
ments appeared to decrease the levels of CD19+IL-10+ (Bregs) and CD19−IL-10+ lymphocytes (Fig. 6b,c) in the 
spleen at this time. However, analysis of a variant (ES3d48) of the ES3 treatment in which lung pathology and 
Breg responses were examined (relative to their OVA controls) at d48 rather than at d69 revealed that whilst 
expected, this intervention had essentially no effect on lung pathology in this short time period (Fig. 6d,e), as 
Figure 6. Induction of IL-10 Bregs is an acute response to ES-62 treatment. (a) Levels of MZ (CD21+CD23±) 
and MZP (CD21+CD23+)-like Bregs are presented as the % of IL-10+ B cells in the spleen in individual ES1-
treated mice (n = 3). (b) The levels of splenic IL-10+ Breg and CD19−IL-10+ lymphocytes in individual ES1, 
ES3 or OVA mice (n = 3). (c) The levels of splenic IL-10+ Breg and CD19−IL-10+ lymphocytes in individual 
naive, OVA or ES2 mice (n = 5). Representative images of H&E (d) and PAS (e) staining of lung sections from 
the OVAd48 and ES3d48 groups. (f) The levels of Bregs presented as the % live cells in individual mice (n = 5) 
and where for the mean ± SEM values, **p < 0.01 and ***p < 0.001 relative to that of the OVA group. In (g), the 
levels of MZ (CD21+CD23±) and MZP (CD21+CD23+)-like Bregs are presented as the % of IL-10+ B cells in the 
spleen in individual mice and where for the mean ± SEM values, *p < 0.05 relative to that of the OVA group.  
(h) Mean values of IL-4 and IL-13 in the BALF of the indicated number of individual mice from the OVAd48 
and ES3d48 groups, demonstrating that the mean ± SEM levels in the ES3d48 group are significantly (*p < 0.05 
and **p < 0.01) different to those in the OVAd48 mice.
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with ES4 treatment the ES3d48 group showed elevated proportions and numbers of IL-10+Bregs (Fig. 6f), spe-
cifically MZ-like Bregs (Fig. 6g) and this immunomodulation was associated with reduced levels of IL-4 and 
IL-13 (Fig. 6h) but not eotaxins, MCP-1 or periostin in the BALF (results not shown: no IL-17 or IL-22 could be 
detected in these airway samples).
Small Molecule Analogues (SMAs) of ES-62 target neutrophil exacerbations associated with 
allergen challenge. As an immunogenic molecule, ES-62 is itself probably unsuitable as a therapeutic: how-
ever, we have recently generated a library of small molecule analogues (SMAs) based on its active PC-moiety13, 
two of which, 11a and 12b can mimic the immunomodulatory activity of ES-62 and suppress allergic inflamma-
tion in models of acute airway6,8,14 and skin hyper-reactivity6,29. SMAs 11a and 12b were therefore tested for their 
ability to suppress the inflammatory exacerbation resulting from the final OVA challenge in this chronic asthma 
model: as with ES-62, such therapeutic treatment with 11a and 12b resulted in reduced cellular infiltration of 
the lungs (Fig. 7a) that reflected a significant reduction in the levels of neutrophils in the BALF (Fig. 7b) and 
was accompanied by restoration of the levels of IL-10+ B cells in the spleen to that seen in naive mice (Fig. 7c). 
Moreover, as observed with ES-62, SMAs 11a and 12b had no effect on the levels of splenic CD19−IL-10+ lympho-
cytes (Fig. 7d). Rather, such therapeutic treatment of mice with SMAs 11a or 12b immediately prior to the final 
OVA challenge, like ES-62 resulted in reduction of the levels of mast cells detected in the lungs (Fig. 7e).
Discussion
Asthma is often described simply as a Th2-polarised eosinophilic inflammatory disease with effector mast cell 
hypersensitivity: however, increasingly it is recognised as a complex, heterogeneous disease encompassing multi-
ple phenotypes including Th2-independent, neutrophilic subgroups that are typically associated with severe and/
or smoking-related asthma as well as those refractory to corticosteroid treatment30. Moreover, unlike acute air-
way contraction, the mucus hyper-production and airway obstruction and remodelling associated with chronic 
asthma appears to be independent of bronchial inflammation. Rather mast cell infiltration of, and interactions 
with, airway smooth muscle (ASM)31 promotes mast cell survival and activation and their differentiation towards 
a fibroblastoid phenotype10,11,32, as well as airway hyper-reactivity (AHR) and ASM remodelling10,11,32. The 
Figure 7. SMAs 11a and 12b ameliorate OVA-induced inflammatory exacerbations. (a) Representative 
images of H&E staining of lung sections from the indicated groups of mice. (b) The proportions and numbers 
of neutrophils in the BALF of individual mice in the indicated treatment groups where *p < 0.05 and **p < 0.01 
relative to the mean ± SEM value of the OVA group. The levels of splenic IL-10+ Breg (c) and CD19−IL-10+ 
lymphocytes (d) presented as the numbers of live cells in individual mice (n = 5) and where for the 
mean ± SEM values, in (c) the OVA group only is significantly different (*p < 0.05) from the control PBS group. 
(e) Representative images of toluidine blue staining of lung sections from the indicated groups of mice and the 
quantitative analysis of the numbers of mast cells in the lungs of individual mice from the indicated treatment 
groups and where data represent the mean numbers of mast cells/section for each mouse, with *p < 0.05 and 
**p < 0.01 relative to that of the OVA group.
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inflammatory microenvironment arising out of ASM-mast cell myositis drives mucous gland hyperplasia, fibro-
sis, collagen deposition and airway thickening, resulting in reduced airway function32. Whilst acute bronchial 
contraction caused by eosinophilic inflammation can be controlled by steroids, the irreversible airway remod-
elling associated with chronic severe asthma is refractory to such conventional therapies33. Thus, there has been 
increasing interest in developing new and more personalised therapies to counter the various subtypes of this 
increasingly economically important group of diseases30,34.
Whilst the incidence of asthma has been rising dramatically in the industrialised world mirroring the control 
of infectious disease in these regions, epidemiological evidence from developing countries suggests that infection 
with helminths may offer some protection against allergic disease: this component of the Hygiene Hypothesis35 is 
further supported by health initiatives like deworming being reflected by recent increases in prevalence of atopy 
in the tropics36. This evolving “story” has therefore recently focused interest both on the potential for therapeutic 
exploitation of such parasitic worms, or their immunomodulatory products, in allergy and asthma and ques-
tioned the wisdom of mass deworming programmes to eradicate helminth-associated morbidity36–38. However, 
despite the wealth of supporting studies in experimental models of airway inflammation, clinical trials investi-
gating the efficacy of ‘worm therapy’ in allergy and asthma have proved disappointing to date4,9,36. This perhaps 
reflects that such therapeutic worm-induced immunomodulation may only target the Th2-mediated inflamma-
tion causing bronchial contractions in acute disease and exacerbations, rather than improving lung function by 
arresting/reversing pathology associated with chronic asthma. Interestingly, therefore, we found that in addition 
to suppressing Th17/Th2-mediated initiation of allergic airway inflammation, ES-62 could also suppress neu-
trophilic airway inflammation and desensitise mast cell responses in acute BALB/c OVA/alum-induced airway 
inflammation6–8. Importantly, exposure to ES-62 could maintain survival of all such treated mice whilst 4 out 
of 6 PBS-treated mice died by d57 in a chronic version39 of this eosinophilic/Th2 model, modified such that the 
BALB/c mice continued to receive OVA intranasally weekly from d21-56 (Kean & Harnett, unpublished). To 
determine whether the mechanisms underpinning such protection involve modulation of airway remodelling, we 
have now investigated whether ES-62 exhibits therapeutic potential in a C57BL/6 model of chronic asthma12, in 
which mice are sensitised to OVA without the use of ALUM adjuvant to avoid hyper-Th2 skewing of the immune 
response, and then challenged weekly with OVA intranasally (until d67) to mimic the pattern of repeated aller-
gen exposure occurring during human disease12. Certainly, such mice develop several of the features associated 
with chronic severe human asthma including mast cell-dependent lung infiltration by lymphocytes, monocytes, 
eosinophils and neutrophils, mucus production and airway remodelling12.
Repeated prophylactic treatment with ES-62, starting prior to intranasal OVA challenge, indeed suppressed 
development of airway remodelling and was associated with reduced cellular, specifically neutrophilic, infiltration 
of the lungs, OVA-specific IgG1 production, mucus (muc5ac and muc5b) hyperproduction and, consistent with 
the observed suppression of periostin production23, airway thickening. The precise mechanisms involved remain 
to be established but as such functional modulation was accompanied by partial reduction of TLR4 and MyD88 
expression in the lungs, this protection presumably reflects, at least in part, the dampening of TLR/MyD88-driven 
airway inflammatory and bronchoconstriction responses26,27,33,40,41, particularly as MyD88 signalling has been 
implicated in promoting neutrophil recruitment33,41 and development of plasma cells16,42,43. In addition, most 
importantly, weekly administration of ES-62, even after airway remodelling had been established, was found 
to at least prevent any further deterioration suggesting that the parasite product can reduce the airway pathol-
ogy associated with chronic asthma. Moreover, the inflammatory exacerbations resulting from repeated allergen 
exposure that are a serious complication of chronic asthma were ameliorated by treatment with ES-62 acting to 
reduce both neutrophilic and mast cell infiltration of the airways, when administered immediately prior to OVA 
challenge during the chronic phase. Intriguingly, this protection is associated with an increase in the levels of B 
cells with the capacity to produce IL-10 and hence putatively, act as regulatory B cells (Bregs): collectively, this is 
reminiscent of the effects observed with therapeutic allergen-induced tolerance (AIT) where mast cell responses 
are suppressed within hours and Bregs are induced within days to effect protection44–46. Bregs can act directly and/
or via the induction or functional restoration of IL-10-producing Tr1 and FoxP3+ regulatory T cells to suppress 
mast cell, neutrophil and eosinophil responses and survival as well as reset effector B and Th cell responses44–47 
and in AIT, some induced Bregs can develop into IgG4-producing cells that act to block IgE-mediated mast cell 
responses44–46. Certainly, regulatory B and T cell populations have been reported to be reduced or dysfunctional 
in atopic subjects44–46,48,49 and consistent with this, although both Bregs and Tr1 cells appear to increase to counter 
the acute initiating inflammatory response, they decline prior to the onset of pathology associated with airway 
remodelling in our mouse model of chronic asthma. Intriguingly, it has recently been recognised that certain 
“helper” neutrophil populations can prime B cell responses and antibody production50 and hence Breg-mediated 
downregulation of neutrophil responses could also potentially contribute to the observed ES-62-mediated sup-
pression of pathogenic OVA-specific IgG1 production.
Indeed, protection against allergic and autoimmune disease by helminths is increasingly recognised as 
involving the mobilisation of Bregs and also, in some cases, consequent regulatory T cell responses38,49,51–54. 
In terms of asthma, in acute eosinophilic (alum adjuvant) models of OVA-induced AHR, the TLR7-elicited 
T2-MZP-like Bregs associated with S. mansoni infection were found to be induced in the spleen, but not the lung 
or lung-draining mediastinal lymph nodes (MLN) of mice and transfer of splenic CD1dhi B cells conferred pro-
tection against AHR in recipient mice in an IL-10- and regulatory T cell-dependent manner 49,51,52. Similarly, with 
respect to the MZ-like Breg population induced by S. mansoni, only those cells isolated from spleens conferred 
protection in an IL-10-dependent manner although in this case, regulatory T cells did not play an essential role 
but rather only promoted suppression of pathology: by contrast, such Bregs harvested from the lungs acted in 
an IL-10- and Treg-independent manner whilst those from MLN did not confer any protection28,49,55. Consistent 
with these data, we found that the protection afforded to mice undergoing OVA-induced AHR with ES-62 or the 
SMAs 11a and 12b during the intranasal challenge phase of the acute alum model8,14 is associated with increased 
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levels of IL-10+Bregs in the spleen (unpublished results). We now show here that ES-62 also acts to dynamically 
induce Bregs, particularly those of the MZ phenotype to counter inflammation throughout the development of 
pathology associated with chronic asthma. Moreover, we have previously shown that the protection afforded by 
ES-62 against the development of autoimmune arthritis and lupus-like nephritis in mouse models16,17 is like-
wise associated with homeostatic resetting of the effector:regulatory B cell balance and that this switch reflects 
a partial downregulation of MyD88 expression16: however, as seen here also, restoration of the levels of Bregs 
to those pertaining in naive healthy mice was not accompanied by a corresponding increase in regulatory Tr1 
cells, but at least in the case of AHR this may reflect the targeting of MZ Bregs which do not appear to require 
regulatory T cells for their action in suppressing lung pathology28. Given that ES-62 therefore generally appears to 
target inflammation by homeostatically resetting resolution of inflammatory responses, it was at first sight rather 
surprising that rather than detecting an increase in Bregs in the ES1 or ES3 treatment groups at d69, if anything 
but presumably reflecting their suppression of pathology, the ES1 and ES3, but not ES2, treatments resulted in a 
reduction in the levels of Bregs. However, as with the ES4 treatment, the increase in MZ-like Bregs in the ES3d48 
group suggests induction of Bregs to be an acute response to ES-62 (and its SMAs) in AHR, that acts to reset the 
homeostatic balance of inflammation and its resolution that is defective in chronic asthma, either in terms of the 
levels or functionality of Bregs48,49,56.
In conclusion, as ES-62 can reduce the airway pathology associated with chronic asthma and ameliorate 
inflammatory exacerbations arising from repeated exposure to allergen, these studies provide a platform for 
developing ES-62-based drugs or those that mimic its actions. To this end we have generated a library of small 
molecule analogues based around the active PC-moiety of ES-62, and we have previously shown two of these, 11a 
and 12b, to mimic its ability to desensitise mast cell responses and afford protection against acute neutrophilic 
airway inflammation and allergic skin inflammation14,29. Now, as SMAs 11a and 12b have both been shown to 
mimic ES-62 in targeting mast cell, neutrophil and Breg responses during inflammatory exacerbations and hence 
potentially, the myositis contributing to airway remodelling in this mouse model, they represent the first step in 
the development of a novel class of drugs to combat the hitherto intractable pathology associated with chronic 
asthma as well as that of steroid refractory patients.
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